Drugs / SR1375
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05421923 | Jun → Oct 2022 | — | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05026008 | Sep 2021 → Nov 2022 | — | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06577558 | Sep 2024 → Oct 2025 overdue | pneumonia | Shanghai SIMR Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SR1375 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05026008 ↗ |
| Route | Oral | “orally administered by single and multiple doses of SR1375 capsules” NCT05026008 ↗ |